N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials
01 Julio 2024 - 7:20AM
Business Wire
• N-Power Medicine to provide oncology clinics
with needed research infrastructure to support Merck's oncology
clinical trials.
N-Power Medicine, a company reinventing the clinical trial
process, is collaborating with Merck, known as MSD outside the
United States and Canada, to enable a greater number of
oncologists, and the patients they care for, to participate in
clinical research. N-Power Medicine’s real-time registry and
point-of-care platform combines technology, AI, and embedded
research staff to deliver an integrated and efficient workflow for
clinical research and routine patient care. Oncology practices in
N-Power Medicine’s Clinical Research Network represent a new kind
of clinical research site, with greater physician participation to
increase access to clinical trials for eligible patients at the
right time.
“We are proud to collaborate with Merck, a company that is
leading innovation in the clinical development process and the
acceleration of transformative medicines to people living with
cancer,” said Mark Lee, M.D., Ph.D, N-Power Co-Founder and Chief
Executive Officer. “This agreement underscores our commitment to
partner with oncology clinics to bring the resources and reinvented
framework that are needed to meaningfully expand access to more
inclusive clinical research.”
N-Power Medicine and Merck are collaborating to implement
multiple trials in the N-Power Medicine Network. The aim will be to
broaden this new model for clinical development to other
indications within oncology and to more cancer centers as the
N-Power Medicine Network grows.
“We look forward to collaborating with N-Power Medicine to
leverage their new approach to expanding clinical research to more
people with cancer,” said Marjorie Green, M.D., Senior Vice
President, Head of Oncology Clinical Development at Merck. “This
provides the opportunity to foster critically-needed innovation in
the cancer care ecosystem with the potential to benefit patients in
urgent need of new therapies.”
Earlier this month, N-Power Medicine announced the initial close
of a Series B funding round, raising its total funding to date to
$72 Million. The Series B round was led by Merck Global Health
Innovation Fund, with participation by a leading US-based
healthcare focused investor. The funds will support the expansion
of the company’s network of oncology clinics and biopharmaceutical
company collaborations leveraging N-Power’s unique platform for
integrating clinical research into everyday patient care.
About N-Power Medicine
N-Power Medicine is a clinical research and drug development
platform company that aims to dramatically boost clinical trial
participation to accelerate oncology drug development – and deliver
on the promise of bringing life-saving innovation to cancer
patients. Founded in 2021, the company addresses critical
challenges for oncology sites by integrating technology and trained
personnel into routine care to unlock the full potential of the
data needed to bring new therapies to patients sooner. For more
information on N-Power Medicine, visit
www.npowermedicine.com and connect with us on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701171060/en/
Ivha Enike-Ekhelar Health+Commerce
ivha@healthandcommerce.com